Multiple stimuli-responsive nanomedicines based on HA have been developed for cancer therapy, such as an enzyme-responsive HA-based nanogel for drug delivery that is preferentially internalized by CD-44-overexpressing cancer cells (Yang et al., 2015). Here, CD44 is linked to cancer.